Clinical data from ongoing Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 ASCO annual meeting
June 4, 2018Updated clinical data show preliminary anti-tumor activity in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1...Outcome of Annual General Meeting of May 29, 2018
May 29, 2018Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 29, 2018, in Marseille, France...Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
May 17, 2018Preliminary activity observed in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1 blockade 3 partial responses...First quarter 2018 report
May 16, 2018Cash, cash equivalents and financial assets of the Company amounted to €153.8 million* Significant momentum across the portfolio, with good progress on the joint monalizumab program with AstraZeneca/...Innate Pharma to hold its Annual General Meeting of Shareholders on May 29, 2018 and the release of its Reference document (in french)
April 30, 2018Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 29, 2018, at 10:00 am in its headquarters, 117 avenue de Luminy...Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN
April 17, 20188 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated,...
